INTRODUCTION: Geographic transferability of model-based cost-effectiveness results may facilitate and shorten the reimbursement process of new pharmaceuticals. This study provides a real world example of transferring a cost-effectiveness study of trastuzumab for the adjuvant treatment of HER2-positive early breast cancer from the United Kingdom to The Netherlands. METHODS: Three successive steps were taken. Step 1: Collect available information with regard to the original model, and assess transferability using existing checklists. Step 2: Adapt transferability-limiting factors. Step 3: Obtain a country-specific estimate of cost-effectiveness. RESULTS: The structure of the UK model was transferable, although some of the model inputs needed adaptation. From a health-care perspective, the Dutch estimate amounted to euro5828/quality-adjusted life-year gained. From a societal perspective, the incremental cost-effectiveness ratio was dominant. CONCLUSION: Transferability of a model-based UK-study in three steps proved to be an efficient method to provide an early indication of the cost-effectiveness of trastuzumab and has led to the provisional reimbursement of the treatment.
INTRODUCTION: Geographic transferability of model-based cost-effectiveness results may facilitate and shorten the reimbursement process of new pharmaceuticals. This study provides a real world example of transferring a cost-effectiveness study of trastuzumab for the adjuvant treatment of HER2-positive early breast cancer from the United Kingdom to The Netherlands. METHODS: Three successive steps were taken. Step 1: Collect available information with regard to the original model, and assess transferability using existing checklists. Step 2: Adapt transferability-limiting factors. Step 3: Obtain a country-specific estimate of cost-effectiveness. RESULTS: The structure of the UK model was transferable, although some of the model inputs needed adaptation. From a health-care perspective, the Dutch estimate amounted to euro5828/quality-adjusted life-year gained. From a societal perspective, the incremental cost-effectiveness ratio was dominant. CONCLUSION: Transferability of a model-based UK-study in three steps proved to be an efficient method to provide an early indication of the cost-effectiveness of trastuzumab and has led to the provisional reimbursement of the treatment.
Authors: Tracy Merlin; Claude Farah; Camille Schubert; Andrew Mitchell; Janet E Hiller; Philip Ryan Journal: Med Decis Making Date: 2012-08-15 Impact factor: 2.583
Authors: M van Nuland; R A Vreman; R M T Ten Ham; A H M de Vries Schultink; H Rosing; J H M Schellens; J H Beijnen; A M Hövels Journal: Breast Cancer Res Treat Date: 2018-07-13 Impact factor: 4.872
Authors: Shanly C Seferina; Bram L T Ramaekers; Maaike de Boer; M Wouter Dercksen; Franchette van den Berkmortel; Roel J W van Kampen; Agnès J van de Wouw; Adri C Voogd; Vivianne C G Tjan Heijnen; Manuela A Joore Journal: Oncotarget Date: 2017-04-09